Catalog No.
EHJ95301
Expression system
Mammalian Cells
Species
Homo sapiens (Human)
Protein length
His65-Ala265
Predicted molecular weight
26.63 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
AAI26290.1
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
CLEC12A, DCAL2, Dendritic cell-associated lectin 2, CLL-1, Myeloid inhibitory C-type lectin-like receptor, C-type lectin domain family 12 member A, CLL1, DCAL-2, C-type lectin-like molecule 1, MICL, CD371
C-type lectin-like molecule-1 as a diagnostic, prognostic, and therapeutic marker in leukemia., PMID:40379983
Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia., PMID:40268927
CLEC12A-directed immunocytokine with target cell-restricted IL-15 activity for treatment of acute myeloid leukemia., PMID:40213559
A review of antibody-based immunotherapy clinical trials for adult acute myeloid leukemia (AML): monoclonal antibodies (mAbs) and beyond., PMID:40069930
Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation., PMID:39896798
Immune-based subgroups uncover diverse tumor immunogenicity and implications for prognosis and precision therapy in acute myeloid leukemia., PMID:39582863
The role of the CLL-1 protein in disease monitoring in patients diagnosed with acute myeloid leukaemia and myelodysplastic syndrome., PMID:39451173
Targeting DUX4-r leukemia via PI3K and CD371., PMID:39325481
Novel Immunotherapy Targets for Relapsed/Refractory B-ALL: A Literature Review., PMID:39222522
Recognition and control of neutrophil extracellular trap formation by MICL., PMID:39143217
Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia., PMID:39095503
Single-cell genomics details the maturation block in BCP-ALL and identifies therapeutic vulnerabilities in DUX4-r cases., PMID:38968149
Small-molecule α-lipoic acid targets ELK1 to balance human neutrophil and erythrocyte differentiation., PMID:38589882
Crystal structure of the complex of CLEC12A and an antibody that interferes with binding of diverse ligands., PMID:38386511
Mechanistic insights into the C-type lectin receptor CLEC12A-mediated immune recognition of monosodium urate crystal., PMID:38367667
A Call for Gene Expression Analysis in Whole Blood of Patients With Rheumatoid Arthritis (RA) as a Biomarker for RA-Associated Interstitial Lung Disease., PMID:38302188
CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment., PMID:38215390
Cooperative CAR targeting to selectively eliminate AML and minimize escape., PMID:37802054
ENPP4 and HOXA3 as potential leukaemia stem cell markers in acute myeloid leukaemia., PMID:37119247
Behçet syndrome: The disturbed balance between anti- (CLEC12A, CLC) and proinflammatory (IFI27) gene expressions., PMID:37102643
Potential biomarkers for the prognosis and treatment of HCC immunotherapy., PMID:36930502
Identification of two early blood biomarkers ACHE and CLEC12A for improved risk stratification of critically ill COVID-19 patients., PMID:36928077
CLEC12A Binds to Legionella pneumophila but Has No Impact on the Host's Antibacterial Response., PMID:36835297
Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms., PMID:36814396
Identification of Potential Differentially-Methylated/Expressed Genes in Chronic Obstructive Pulmonary Disease., PMID:36655999
Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells., PMID:36563336
Mycobacterial mycolic acids trigger inhibitory receptor Clec12A to suppress host immune responses., PMID:36542980
Understanding inhibitory receptor function in neutrophils through the lens of CLEC12A., PMID:36424898
Single-cell RNA-sequencing of peripheral blood mononuclear cells reveals widespread, context-specific gene expression regulation upon pathogenic exposure., PMID:35672358
CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia., PMID:35481814
[Development and functional verification of CAR-T cells targeting CLL-1]., PMID:35381669
Immunophenotypically defined stem cell subsets in paediatric AML are highly heterogeneous and demonstrate differences in BCL-2 expression by cytogenetic subgroups., PMID:35298835
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL., PMID:35288466
Identification of potential blood biomarkers for early diagnosis of schizophrenia through RNA sequencing analysis., PMID:35016150
The Fusion of CLEC12A and MIR223HG Arises from a trans-Splicing Event in Normal and Transformed Human Cells., PMID:34830054
DNA crosslinking and recombination-activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemia., PMID:34699692
Regulation of the Expression, Oligomerisation and Signaling of the Inhibitory Receptor CLEC12A by Cysteine Residues in the Stalk Region., PMID:34638548
Arsenic exposure and human blood DNA methylation and hydroxymethylation profiles in two diverse populations from Bangladesh and Spain., PMID:34516978
Modeling a disease-correlated tubulin mutation in budding yeast reveals insight into MAP-mediated dynein function., PMID:34379441
Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia In Vitro and In Vivo., PMID:34253594
The Inhibitory Receptor CLEC12A Regulates PI3K-Akt Signaling to Inhibit Neutrophil Activation and Cytokine Release., PMID:34234773
Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients., PMID:34053123
Expression of the myeloid inhibitory receptor CLEC12A correlates with disease activity and cytokines in early rheumatoid arthritis., PMID:34045571
C-Type Lectin-Like Molecule-1 as a Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia: A Preliminary Study., PMID:33778076
A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia., PMID:33617672
Cytotoxic effect of CLL‑1 CAR‑T cell immunotherapy with PD‑1 silencing on relapsed/refractory acute myeloid leukemia., PMID:33495835
Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy., PMID:33369070
Antigen Expression Varies Significantly between Molecular Subgroups of Acute Myeloid Leukemia Patients: Clinical Applicability Is Hampered by Establishment of Relevant Cutoffs., PMID:33271547
Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes., PMID:33220589
A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells., PMID:33097838
For research use only. Not for human or drug use.
